Polymorphisms of tumor necrosis factor receptor 2 are not associated with insulin-dependent diabetes mellitus or Graves' disease

Tissue Antigens

Volumn 49, Issue 5, 1997, Pages 535-536

  Rau, H ^a   Donner, H ^a   Usadel, K H ^a   Badenhoop, K ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Autoimmunity; Genetic susceptibility; Graves' disease; HLA; IDDM; Insulin dependent diabetes mellitus; MHC; Tumor necrosis factor receptor 2

Indexed keywords

TUMOR NECROSIS FACTOR RECEPTOR;

ALLELE; ARTICLE; AUTOIMMUNITY; DNA SEQUENCE; ENDOCRINE DISEASE; GENETIC SUSCEPTIBILITY; GRAVES DISEASE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0031011539     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1997.tb02795.x     Document Type: Article

References (15)

1. Badenhoop K, Walfish PG, Rau H et al. Susceptibility and resistance alleles of HLA DQA1 and HLA DQB1 are shared in endocrine autoimmune disease. J Clin Endocrinol Metab 1995: 80: 2112-7.
2. Todd JA, Bell JI, McDevitt HO. HLA-DQβ gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987: 329: 599-604.
3. Khalil I, Deschamps I, Lepage V, Al-Daccak R, Degos L, Hors J. Dose effect of cis- and trans-encoded HLA-DQα/β heterodimers in IDDM susceptibility. Diabetes 1992: 41: 378-84.
4. Badenhoop K, Schwarz G, Trowsdale J et al. TNF-α gene polymorphisms in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1989: 32: 445-8.
5. Badenhoop K, Schwarz G, Schleusener H et al. Tumor necrosis factor β gene polymorphisms in Graves' disease. J Clin Endocrinol Metab 1992: 74: 287-91.
6. Kaufman BA, White PS, Steinbrueck T, Donis-Keller H, Brodeur GM. Linkage mapping of the tumor necrosis factor receptor 2 (TNFR2) gene to 1p36.2 using the single-strand conformation polymorphism technique. Hum Genet 1994: 94: 418-22.
7. Abe Y, Watanabe Y, Kimura S. The role of tumor necrosis factor receptors in cell signalling and the significance of soluble form levels in the serum. Surg Today 1994: 24: 197-202.
8. Fuchs P, Strehl S, Dworzak M, Himmler A, Ambros PF. Structure of the human TNF receptor 1 (p60) gene (TNFR1) and localization to chromosome 12p13. Genomics 1992: 13: 219-24.
9. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumor necrosis factor in clinically laboratory diagnosis. Eur J Haematol 1995: 54: 1-8.
10. Roux-Lombard P, Lin HC, Peter JB, Dayer JM. Elevated serum levels of TNF soluble receptors in patients with positive anti-neutrophil cytoplasmic antibodies. Br J Rheumatol 1994: 33: 428-31.
11. Heilig B, Fiehn C, Brockhaus M, Gallati H, Pezzutto A, Hunstein W. Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease. J Clin Immunol 1993: 13: 321-8.
12. Mandrup-Poulsen T, Pociot F, Molvig J et al. Monokine antagonism is reduced in patients with IDDM. Diabetes 1994: 43: 1242-7.
13. Selmaj KW, Raine CS. Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 1995: 45: S44-9.
14. Selmaj KW, Papierz W, Glabinski A, Kohno T. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor 1. J Neuroimmunol 1995: 56: 135-41.
15. Wooley PH, Dutcher J, Widmer MB, Gillis S. Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type 2 collagen-induced arthritis in mice. J Immunol 1993: 151: 6602-7.